Palobiofarma SL

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
Adenosine A1 receptor
Chronic Obstructive Pulmonary DiseaseAsthma
Phase 1
Adenosine A2b receptorSmall molecule
Non-Small Cell Lung Cancer
PBF-1650No recent activity
Phase 1
Adenosine A3 receptor (antagonist)Small molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.